CTNM
Contineum Therapeutics, Inc.
Price Chart
Latest Quote
$11.94
-0.22 (-1.81%)
Current Price
| Previous Close | $12.16 |
| Open | $12.30 |
| Day High | $12.67 |
| Day Low | $11.57 |
| Volume | 313,870 |
Stock Information
| Shares Outstanding | 32.72M |
| Total Debt | $6.95M |
| Cash Equivalents | $246.33M |
| Net Income | $-58.44M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $446.39M |
| EPS (TTM) | $-1.95 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $207.02M |
| Income | $-58.44M |
| Book/sh | $6.69 |
| Cash/sh | $7.53 |
| Employees | 51 |
Financial Ratios
| Quick Ratio | 37.00 |
| Current Ratio | 38.00 |
| Debt/Eq | 2.78 |
Returns & Margins
| ROA | -18.18% |
| ROE | -26.88% |
Ownership
| Insider Ownership | 0.96% |
| Institutional Ownership | 93.99% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.58 |
| P/B | 1.79 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $22.33 |
Technical Indicators
| SMA20 | $12.56 |
| SMA50 | $13.03 |
| SMA200 | $12.50 |
| RSI | 33.40 |
| ATR | 0.9376 |
| Shares Float | 27.60M |
| Short Float | 4.40% |
| Short Ratio | 7.65 |
| Volatility | 0.89 |
| Rel Volume | 1.40 |
Performance History
| Week | +0.67% |
| Month | -6.43% |
| Quarter | -1.40% |
| 6 Months | +3.38% |
| YTD | +4.83% |
| Year | +203.82% |
| 10 Years | -22.47% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $11.94 | 313,900 |
| 2026-06-17 | $12.16 | 200,900 |
| 2026-06-16 | $12.40 | 590,900 |
| 2026-06-15 | $12.72 | 430,200 |
| 2026-06-12 | $11.88 | 109,500 |
| 2026-06-11 | $11.86 | 127,400 |
| 2026-06-10 | $11.30 | 136,400 |
| 2026-06-09 | $11.43 | 202,900 |
| 2026-06-08 | $11.53 | 97,500 |
| 2026-06-05 | $11.49 | 285,400 |
| 2026-06-04 | $12.34 | 245,800 |
| 2026-06-03 | $12.48 | 434,300 |
| 2026-06-02 | $12.38 | 242,300 |
| 2026-06-01 | $13.09 | 130,700 |
| 2026-05-29 | $13.49 | 100,700 |
| 2026-05-28 | $13.31 | 91,600 |
| 2026-05-27 | $13.44 | 148,400 |
| 2026-05-26 | $13.70 | 209,900 |
| 2026-05-22 | $13.86 | 220,300 |
| 2026-05-21 | $14.37 | 155,900 |
| 2026-05-20 | $13.39 | 202,400 |
| 2026-05-19 | $12.76 | 111,900 |
About Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
đ° Latest News
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Zacks âĸ 2026-06-02T13:40:03Z
Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?
Zacks âĸ 2026-05-25T13:55:02Z
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential
MarketBeat âĸ 2026-05-22T12:03:58Z
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Zacks âĸ 2026-05-15T13:40:02Z
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet
Zacks âĸ 2026-05-08T13:55:04Z
We Think Contineum Therapeutics (NASDAQ:CTNM) Can Afford To Drive Business Growth
Simply Wall St. âĸ 2026-04-19T12:03:52Z
Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference
MarketBeat âĸ 2026-03-15T01:04:12Z
Beat the Market the Zacks Way: Contineum Therapeutics, Suzano, PepsiCo in Focus
Zacks âĸ 2026-03-02T13:25:00Z
Is Contineum Therapeutics, Inc. (CTNM) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2026-02-04T14:40:03Z
Contineum Therapeutics, Inc. (NASDAQ:CTNM) surges 10%; retail investors who own 51% shares profited along with institutions
Simply Wall St. âĸ 2026-01-27T15:22:15Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $50,000,000 | $0 |
| Operating Revenue | $0 | $0 | $50,000,000 | $0 |
| Expenses | ||||
| Total Expenses | $68,059,000 | $50,894,000 | $33,923,000 | $22,720,000 |
| Other Income Expense | $-165,000 | $-269,000 | $2,695,000 | $-1,906,000 |
| Other Non Operating Income Expenses | $-165,000 | $-163,000 | $-177,000 | $-92,000 |
| Net Non Operating Interest Income Expense | $8,246,000 | $8,905,000 | $4,398,000 | $373,000 |
| Operating Expense | $68,059,000 | $50,894,000 | $33,923,000 | $22,720,000 |
| General And Administrative Expense | $16,537,000 | $12,472,000 | $6,320,000 | $5,826,000 |
| Interest Expense | - | $0 | $208,000 | $388,000 |
| Interest Expense Non Operating | - | $0 | $208,000 | $388,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-59,978,000 | $-42,258,000 | $22,720,000 | $-24,253,000 |
| Net Interest Income | $8,246,000 | $8,905,000 | $4,398,000 | $373,000 |
| Interest Income | $8,246,000 | $8,905,000 | $4,606,000 | $761,000 |
| Normalized Income | $-59,978,000 | $-42,152,000 | $19,903,779 | $-22,439,000 |
| Net Income From Continuing And Discontinued Operation | $-59,978,000 | $-42,258,000 | $22,720,000 | $-24,253,000 |
| Total Operating Income As Reported | $-68,059,000 | $-50,894,000 | $-16,077,000 | $-22,720,000 |
| Net Income Common Stockholders | $-59,978,000 | $-42,258,000 | $22,720,000 | $-24,253,000 |
| Net Income | $-59,978,000 | $-42,258,000 | $22,720,000 | $-24,253,000 |
| Net Income Including Noncontrolling Interests | $-59,978,000 | $-42,258,000 | $22,720,000 | $-24,253,000 |
| Net Income Continuous Operations | $-59,978,000 | $-42,258,000 | $22,720,000 | $-24,253,000 |
| Pretax Income | $-59,978,000 | $-42,258,000 | $23,170,000 | $-24,253,000 |
| Interest Income Non Operating | $8,246,000 | $8,905,000 | $4,606,000 | $761,000 |
| Operating Income | $-68,059,000 | $-50,894,000 | $16,077,000 | $-22,720,000 |
| Special Income Charges | - | $0 | $2,867,000 | $-1,817,000 |
| Per Share | ||||
| Diluted EPS | $-2.17 | $-2.18 | $0.84 | $-1.45 |
| Basic EPS | $-2.17 | $-2.18 | $0.84 | $-1.45 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $55,779 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-67,736,000 | $-50,530,000 | $20,701,000 | $-21,722,000 |
| Reconciled Depreciation | $323,000 | $258,000 | $195,000 | $329,000 |
| EBITDA (Bullshit earnings) | $-67,736,000 | $-50,636,000 | $23,573,000 | $-23,536,000 |
| EBIT | $-68,059,000 | $-50,894,000 | $23,378,000 | $-23,865,000 |
| Diluted Average Shares | $27,700,855 | $19,352,859 | $27,055,790 | $17,760,690 |
| Basic Average Shares | $27,700,855 | $19,352,859 | $27,055,790 | $16,674,148 |
| Diluted NI Availto Com Stockholders | $-59,978,000 | $-42,258,000 | $22,720,000 | $-24,253,000 |
| Research And Development | $51,522,000 | $38,422,000 | $27,603,000 | $16,894,000 |
| Selling General And Administration | $16,537,000 | $12,472,000 | $6,320,000 | $5,826,000 |
| Other Gand A | $16,537,000 | $12,472,000 | $6,320,000 | $5,826,000 |
| Total Unusual Items | - | $-106,000 | $2,872,000 | $-1,814,000 |
| Total Unusual Items Excluding Goodwill | - | $-106,000 | $2,872,000 | $-1,814,000 |
| Tax Provision | - | $0 | $450,000 | $0 |
| Gain On Sale Of Security | - | $-106,000 | $5,000 | $3,000 |
| Other Special Charges | - | - | $-2,867,000 | $1,817,000 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $260,989,000 | $198,066,000 | $-67,936,000 | $-93,212,000 |
| Total Assets | $276,642,000 | $212,847,000 | $130,386,000 | $50,636,000 |
| Total Non Current Assets | $8,725,000 | $6,459,000 | $2,680,000 | $2,244,000 |
| Other Non Current Assets | $256,000 | $3,000 | $1,283,000 | $129,000 |
| Current Assets | $267,917,000 | $206,388,000 | $127,706,000 | $48,392,000 |
| Other Current Assets | $5,021,000 | $1,628,000 | $2,516,000 | $1,153,000 |
| Cash Cash Equivalents And Short Term Investments | $262,896,000 | $204,760,000 | $125,190,000 | $47,239,000 |
| Cash And Cash Equivalents | $75,603,000 | $21,943,000 | $15,526,000 | $5,569,000 |
| Debt | ||||
| Total Debt | $8,250,000 | $6,259,000 | $572,000 | $5,849,000 |
| Long Term Debt And Capital Lease Obligation | $5,909,000 | $4,807,000 | $108,000 | $791,000 |
| Current Debt And Capital Lease Obligation | $2,341,000 | $1,452,000 | $464,000 | $5,058,000 |
| Current Debt | - | - | - | $3,948,000 |
| Other Current Borrowings | - | - | - | $3,948,000 |
| Net Debt | - | - | - | - |
| Long Term Debt | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $15,653,000 | $14,781,000 | $198,322,000 | $143,848,000 |
| Total Non Current Liabilities Net Minority Interest | $5,909,000 | $4,807,000 | $192,838,000 | $136,298,000 |
| Current Liabilities | $9,744,000 | $9,974,000 | $5,484,000 | $7,550,000 |
| Payables And Accrued Expenses | $2,607,000 | $5,184,000 | $3,116,000 | $1,182,000 |
| Payables | $1,016,000 | $1,811,000 | $635,000 | $430,000 |
| Accounts Payable | $1,016,000 | $1,811,000 | $635,000 | $430,000 |
| Other Non Current Liabilities | - | - | $110,000 | $3,025,000 |
| Current Deferred Liabilities | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $260,989,000 | $198,066,000 | $-67,936,000 | $-93,212,000 |
| Total Equity Gross Minority Interest | $260,989,000 | $198,066,000 | $-67,936,000 | $-93,212,000 |
| Stockholders Equity | $260,989,000 | $198,066,000 | $-67,936,000 | $-93,212,000 |
| Gains Losses Not Affecting Retained Earnings | $260,000 | $71,000 | $108,000 | $-76,000 |
| Other Equity Adjustments | $260,000 | $71,000 | $108,000 | $-76,000 |
| Retained Earnings | $-177,380,000 | $-117,402,000 | $-75,144,000 | $-97,864,000 |
| Preferred Securities Outside Stock Equity | - | $0 | $192,620,000 | $132,482,000 |
| Other | ||||
| Ordinary Shares Number | $37,320,125 | $25,854,549 | $27,055,790 | $27,055,790 |
| Share Issued | $37,320,125 | $25,854,549 | $27,055,790 | $27,055,790 |
| Tangible Book Value | $260,989,000 | $198,066,000 | $-67,936,000 | $-93,212,000 |
| Invested Capital | $260,989,000 | $198,066,000 | $-67,936,000 | $-89,264,000 |
| Working Capital | $258,173,000 | $196,414,000 | $122,222,000 | $40,842,000 |
| Capital Lease Obligations | $8,250,000 | $6,259,000 | $572,000 | $1,901,000 |
| Total Capitalization | $260,989,000 | $198,066,000 | $-67,936,000 | $-93,212,000 |
| Additional Paid In Capital | $438,072,000 | $315,371,000 | $7,098,000 | $4,726,000 |
| Capital Stock | $37,000 | $26,000 | $2,000 | $2,000 |
| Common Stock | $37,000 | $26,000 | $2,000 | $2,000 |
| Preferred Stock | $0 | $0 | $0 | - |
| Long Term Capital Lease Obligation | $5,909,000 | $4,807,000 | $108,000 | $791,000 |
| Current Capital Lease Obligation | $2,341,000 | $1,452,000 | $464,000 | $1,110,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,796,000 | $3,338,000 | $1,904,000 | $1,310,000 |
| Current Accrued Expenses | $1,591,000 | $3,373,000 | $2,481,000 | $752,000 |
| Net PPE | $8,469,000 | $6,456,000 | $1,397,000 | $2,115,000 |
| Accumulated Depreciation | $-1,963,000 | $-1,717,000 | $-1,477,000 | $-1,280,000 |
| Gross PPE | $10,432,000 | $8,173,000 | $2,874,000 | $3,395,000 |
| Leases | $177,000 | $175,000 | $48,000 | $18,000 |
| Other Properties | $9,954,000 | $7,711,000 | $2,771,000 | $3,349,000 |
| Machinery Furniture Equipment | $301,000 | $287,000 | $55,000 | $28,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $187,293,000 | $182,817,000 | $109,664,000 | $41,670,000 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-55,543,000 | $-33,359,000 | $18,935,000 | $-20,239,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-55,312,000 | $-32,845,000 | $19,349,000 | $-20,121,000 |
| Cash Flow From Continuing Operating Activities | $-55,312,000 | $-32,845,000 | $19,349,000 | $-20,121,000 |
| Operating Gains Losses | $55,000 | $85,000 | $14,000 | $-7,000 |
| Investing Activities | ||||
| Capital Expenditure | $-231,000 | $-514,000 | $-414,000 | $-118,000 |
| Investing Cash Flow | $-3,713,000 | $-69,739,000 | $-65,568,000 | $22,299,000 |
| Cash Flow From Continuing Investing Activities | $-3,713,000 | $-69,739,000 | $-65,568,000 | $22,299,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $112,255,000 | $108,211,000 | $60,138,000 | $0 |
| Financing Cash Flow | $112,685,000 | $109,001,000 | $56,176,000 | $-1,239,000 |
| Cash Flow From Continuing Financing Activities | $112,685,000 | $109,001,000 | $56,176,000 | $-1,239,000 |
| Net Other Financing Charges | $-256,000 | - | $-343,000 | - |
| Net Common Stock Issuance | $112,255,000 | $108,211,000 | $-28,000 | $-4,000 |
| Common Stock Issuance | $112,255,000 | $108,211,000 | $0 | - |
| Repurchase Of Capital Stock | - | $0 | $-28,000 | $-4,000 |
| Net Preferred Stock Issuance | - | $0 | $60,138,000 | $0 |
| Preferred Stock Issuance | - | $0 | $60,138,000 | $0 |
| Other | ||||
| End Cash Position | $75,603,000 | $21,943,000 | $15,526,000 | $5,569,000 |
| Beginning Cash Position | $21,943,000 | $15,526,000 | $5,569,000 | $4,630,000 |
| Changes In Cash | $53,660,000 | $6,417,000 | $9,957,000 | $939,000 |
| Proceeds From Stock Option Exercised | $686,000 | $790,000 | $159,000 | $15,000 |
| Net Investment Purchase And Sale | $-3,482,000 | $-69,245,000 | $-65,154,000 | $22,417,000 |
| Sale Of Investment | $159,020,000 | $157,162,000 | $76,712,000 | $87,116,000 |
| Purchase Of Investment | $-162,502,000 | $-226,407,000 | $-141,866,000 | $-64,699,000 |
| Net PPE Purchase And Sale | $-231,000 | $-494,000 | $-414,000 | $-118,000 |
| Sale Of PPE | $0 | $20,000 | $0 | - |
| Purchase Of PPE | $-231,000 | $-514,000 | $-414,000 | $-118,000 |
| Change In Working Capital | $-6,039,000 | $5,334,000 | $-1,024,000 | $-1,267,000 |
| Change In Other Current Liabilities | $-1,261,000 | $66,000 | $-1,348,000 | $-925,000 |
| Change In Other Current Assets | $3,000 | $937,000 | $7,000 | $-32,000 |
| Change In Payables And Accrued Expense | $-1,385,000 | $3,444,000 | $1,594,000 | $68,000 |
| Change In Accrued Expense | $-516,000 | $2,303,000 | $1,594,000 | $298,000 |
| Change In Payable | $-869,000 | $1,141,000 | - | $-230,000 |
| Change In Account Payable | $-869,000 | $1,141,000 | $0 | $-230,000 |
| Change In Prepaid Assets | $-3,396,000 | $887,000 | $-1,277,000 | $-378,000 |
| Other Non Cash Items | $1,080,000 | $872,000 | $-2,100,000 | $2,898,000 |
| Stock Based Compensation | $10,038,000 | $6,804,000 | $2,219,000 | $1,927,000 |
| Amortization Of Securities | $-791,000 | $-3,940,000 | $-2,675,000 | $252,000 |
| Depreciation Amortization Depletion | $323,000 | $258,000 | $195,000 | $329,000 |
| Depreciation And Amortization | $323,000 | $258,000 | $195,000 | $329,000 |
| Gain Loss On Investment Securities | $-12,000 | $101,000 | $14,000 | $-9,000 |
| Gain Loss On Sale Of PPE | $67,000 | $-16,000 | $0 | $2,000 |
| Net Income From Continuing Operations | $-59,978,000 | $-42,258,000 | $22,720,000 | $-24,253,000 |
| Repayment Of Debt | - | $0 | $-3,750,000 | $-1,250,000 |
| Interest Paid Supplemental Data | - | $0 | $150,000 | $225,000 |
| Income Tax Paid Supplemental Data | - | $0 | $450,000 | $0 |
| Common Stock Payments | - | $0 | $-28,000 | $-4,000 |
| Net Issuance Payments Of Debt | - | $0 | $-3,750,000 | $-1,250,000 |
| Net Long Term Debt Issuance | - | $0 | $-3,750,000 | $-1,250,000 |
| Long Term Debt Payments | - | $0 | $-3,750,000 | $-1,250,000 |
| Net Short Term Debt Issuance | - | - | $-3,750,000 | $-1,250,000 |
| Short Term Debt Payments | - | - | $-3,750,000 | $-1,250,000 |
Fetched: 2026-06-19